Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:14 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,144 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Grippe Clear all
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Development of Immune Globulin Treatment for Avian Flu

NCT00383071
View directory record Official record
Conditions
Infectious Diseases, Influenza, Avian Flu
Interventions
H5N1 vaccine, Apheresis
Biological · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Nov 3, 2026, 4:14 PM EST
Completed No phase listed Observational

A Pilot Study of Influenza Viruses Isolated From Immunocompromised Children and Adolescents

NCT02352389
View directory record Official record
Conditions
Influenza, Human
Interventions
Blood sample, Nasal swab, Oropharyngeal swab, Stool sample, Symptom checklist
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Nov 3, 2026, 4:14 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine

NCT00521586
View directory record Official record
Conditions
Influenza
Interventions
13 valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 59 Years
Enrollment
1,116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
41
States / cities
Chandler, Arizona • Rolling Hills Estates, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Nov 3, 2026, 4:14 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

NCT02213354
View directory record Official record
Conditions
Avian Influenza
Interventions
MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years to 99 Years
Enrollment
479 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Nov 3, 2026, 4:14 PM EST
Completed Not applicable Interventional

Electronic Health Records for Health Promotion

NCT00142077
View directory record Official record
Conditions
Influenza
Interventions
Electronic health record and messaging system
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2007 · Synced Nov 3, 2026, 4:14 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively

NCT04109222
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation, Fluzone High-Dose vaccine, 2019-2020 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 83 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Nov 3, 2026, 4:14 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Escalating Study of DAS181 in Adults

NCT00527865
View directory record Official record
Conditions
Influenza
Interventions
DAS181, Placebo
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2009 · Synced Nov 3, 2026, 4:14 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults

NCT05397119
View directory record Official record
Conditions
Influenza, Pandemic
Interventions
BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN, rH5 (100 µg) control - pipette - IN, Saline (Placebo) - pipette - IN, H5N1 IIV - IM
Biological
Lead sponsor
BlueWillow Biologics
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 3, 2026, 4:14 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59

NCT06560151
View directory record Official record
Conditions
Influenza
Interventions
3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A, 3.75 µg H5N1 antigen plus MF59, 7.5 µg H5N1 antigen plus MF59, 15 µg H5N1 antigen plus MF59
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years and older
Enrollment
1,380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
20
States / cities
Atlanta, Georgia • Savannah, Georgia • Oak Lawn, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 3, 2026, 4:14 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Prompt to Bundle COVID-19 Booster and Flu Shot

NCT05586165
View directory record Official record
Conditions
COVID-19, Vaccines
Interventions
Reminder to boost protection against COVID-19, Flu Tag Along, COVID-19 Booster & Flu Bundle
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
109,493 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Nov 3, 2026, 4:14 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections

NCT07610967
View directory record Official record
Conditions
COVID-19 Respiratory Infection, Influenza
Interventions
RD-X19, RD-X19 Sham
Device
Lead sponsor
David Moss
Federal
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 3, 2026, 4:14 PM EST
Completed No phase listed Observational

Performance Evaluation of LumiraDx SARS-CoV-2, Flu A/B, and RSV Tests for COVID-19 Assessment

NCT05268939
View directory record Official record
Conditions
COVID-19, Influenza A, Influenza Type B, RSV Infection
Interventions
LumiraDx SARS-CoV-2 & Flu A/B test, LumiraDx SARS-CoV-2 & RSV test
Diagnostic Test
Lead sponsor
LumiraDx UK Limited
Industry
Eligibility
Not listed
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Cullman, Alabama • Encinitas, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 3, 2026, 4:14 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

NCT03293498
View directory record Official record
Conditions
Influenza
Interventions
NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21, Saline - Day 21
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Raleigh, North Carolina • Rocky Mount, North Carolina • Statesville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Nov 3, 2026, 4:14 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age

NCT00946101
View directory record Official record
Conditions
Influenza
Interventions
MEDI3414 [Influenza A(H1N1) live attenuated, intranasal], Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
16
States / cities
Mobile, Alabama • Sacramento, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Nov 3, 2026, 4:14 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects

NCT01179919
View directory record Official record
Conditions
Obesity
Interventions
Oseltamivir
Drug
Lead sponsor
Manjunath Prakash Pai
Other
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Paramaus, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Nov 3, 2026, 4:14 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

NCT00192309
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T, TIV, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Nov 3, 2026, 4:14 PM EST
Completed Not applicable Interventional Results available

Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza

NCT00555893
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
1 Year to 79 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Nov 3, 2026, 4:14 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Home Testing of Respiratory Illness

NCT04245800
View directory record Official record
Conditions
Influenza -Like Illness, Influenza A, Influenza Type B, Respiratory Viral Infection, Respiratory Tract Infections
Interventions
Not listed
Lead sponsor
Evidation Health
Industry
Eligibility
18 Years and older
Enrollment
5,233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Nov 3, 2026, 4:14 PM EST
Withdrawn Phase 1 Interventional

A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer

NCT05600582
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
CodaLytic
Biological
Lead sponsor
Codagenix, Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Nov 3, 2026, 4:14 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza

NCT05052697
View directory record Official record
Conditions
Influenza, Human
Interventions
mIRV, bIRV AB, qIRV, QIV, bIRV AA, bIRV BB
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
100
States / cities
Athens, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Nov 3, 2026, 4:14 PM EST
Not listed No phase listed Observational

The DETECT(Digital Engagement & Tracking for Early Control, & Treatment) Study

NCT04336020
View directory record Official record
Conditions
Influenza, Virus
Interventions
Not listed
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Nov 3, 2026, 4:14 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children

NCT01196988
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 17 Years
Enrollment
3,027 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
14
States / cities
Sacramento, California • Boca Raton, Florida • Wichita, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Nov 3, 2026, 4:14 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous RZV and aIIV4 Vaccination

NCT05007041
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
Interventions
FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Nov 3, 2026, 4:14 PM EST
Not listed Phase 4 Interventional Accepts healthy volunteers

High-Dose Influenza Vaccine in Nursing Homes

NCT01815268
View directory record Official record
Conditions
Influenza
Interventions
HD Vaccine, SD Vaccine, Free Vaccine, Usual Care
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
823 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
3
States / cities
Cleveland, Ohio • Providence, Rhode Island • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Nov 3, 2026, 4:14 PM EST